Key Decisions for Life Science Companies: Stay the Course or Exit via M&A?
By , , ,

This article is the fourth in a 4-part series reviewing financing solutions for the Life Science sector. Many life science companies are fortunate to reach a critical inflection point where leadership must face a decision: continue to fund growth to reach clinical milestones independently or exit via merger and acquisition….Read More

Read More
Creative Financing Approaches in Life Science
By , , ,

This article is the third in a 4-part series reviewing financing solutions for the Life Science sector. As Life Science company valuations have fluctuated significantly over the last two years, and investors have become cautious due to economic turbulence and market uncertainty, fundraising is taking longer. Equity financing has been…Read More

Read More
Life Sciences Companies: Sell Now or Sell Later?
By

Life sciences companies in their early stages are in constant need of capital to continue along their path to meeting clinical milestones. Most are pre-revenue and focused on successful completion of Phase I and II clinical trials. And with strong clinical data, these investment prospects are attractive to sources of…Read More

Read More